{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:04:10Z","timestamp":1784091850576,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare the efficacy of two topical NSAID eye drops, Bromfenac and Nepafenac, in reducing postoperative pain following transepithelial photorefractive keratectomy (t-PRK).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 119 patients undergoing bilateral t-PRK were divided into three groups: Nepafenac (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940), Bromfenac (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940), or control (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200939). Nepafenac 0.1% three times daily or Bromfenac 0.07% twice daily, initiated two days preoperatively and continued for three days postoperatively. The control group received systemic paracetamol (500\u00a0mg) and ibuprofen (150\u00a0mg) tablets as needed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, both Nepafenac and Bromfenac groups showed significantly lower mean pain levels compared with control group (mean difference = -2.77; 95% CI: \u22123.63 to \u2212\u20091.91;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, and mean difference = -2.22; 95% CI: -3.01 to -1.43;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively). Bromfenac was significantly superior to control only on days 1, 3, and 4. No statistically significant difference in mean pain levels was observed between Bromfenac and Nepafenac groups (mean difference = -0.55; 95% CI: -1.45 to 0.35;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.234). While Nepafenac showed better early symptom control in pain and discomfort (stinging, tearing and light sensitivity), particularly in the first two postoperative days, Bromfenac had a better effect on ocular discomfort in the later postoperative phase on days 4 and 5. Both demonstrated comparable overall tolerability compared to the control.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both Nepafenac and Bromfenac significantly reduced postoperative pain following t-PRK compared to systemic analgesia. These findings support the use of topical NSAIDs in optimizing post-PRK pain management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07375-1","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:08:24Z","timestamp":1784088504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bromfenac versus nepafenac for pain management following transepithelial photorefractive keratectomy"],"prefix":"10.1007","author":[{"given":"Asaf","family":"Achiron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Kagasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Barequet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Klinghoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Yahalomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Eilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Zitron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliya","family":"Levinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"7375_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-vision-111815-114358","volume":"2","author":"D Palanker","year":"2016","unstructured":"Palanker D (2016) Evolution of Concepts and Technologies in Ophthalmic Laser Therapy. Annu Rev Vis Sci 2:295\u2013319. https:\/\/doi.org\/10.1146\/annurev-vision-111815-114358 PubMed PMID: 28532364","journal-title":"Annu Rev Vis Sci"},{"issue":"4","key":"7375_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40123-021-00383-w","volume":"10","author":"M Moshirfar","year":"2021","unstructured":"Moshirfar M, Tukan AN, Bundogji N, Liu HY, McCabe SE, Ronquillo YC et al (2021) Ectasia After Corneal Refractive Surgery: A Systematic Review. Ophthalmol Ther 10(4):753\u2013776. https:\/\/doi.org\/10.1007\/s40123-021-00383-w","journal-title":"Ophthalmol Ther"},{"key":"7375_CR3","unstructured":"Somani SN, Moshirfar M, Patel BC Photorefractive Keratectomy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Aug 9]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549887\/ PubMed PMID: 31751077"},{"key":"7375_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/B978-1-4377-0603-1.00034-X","volume-title":"Retinal Pharmacotherapy [Internet]","author":"EB Rodrigues","year":"2010","unstructured":"Rodrigues EB, Farah ME, Bott\u00f3s JM, Aggio FB (2010) Nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of retinal diseases. Retinal Pharmacotherapy [Internet]. Elsevier, pp 196\u2013200. https:\/\/doi.org\/10.1016\/B978-1-4377-0603-1.00034-X"},{"issue":"2","key":"7375_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/ICO.0000000000000704","volume":"35","author":"R Garcia","year":"2016","unstructured":"Garcia R, Horovitz RNC, Torricelli AAM, Mukai A, Bechara SJ (2016) Improved Evaluation of Postoperative Pain After Photorefractive Keratectomy. Cornea 35(2):205\u2013209. https:\/\/doi.org\/10.1097\/ICO.0000000000000704","journal-title":"Cornea"},{"issue":"4","key":"7375_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/ICU.0000000000000486","volume":"29","author":"O Golan","year":"2018","unstructured":"Golan O, Randleman JB (2018) Pain management after photorefractive keratectomy. Curr Opin Ophthalmol 29(4):306\u2013312. 101097\/ICU.0000000000000486 PubMed PMID: 29708926","journal-title":"Curr Opin Ophthalmol"},{"key":"7375_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2147\/OPTH.S255441","volume":"14","author":"M Ripa","year":"2020","unstructured":"Ripa M, Betts B, Dhaliwal S, Wang K, Pouly S, Chen D et al (2020) Survey of Postoperative Pain in Photorefractive Keratectomy Using Topical versus Oral Nonsteroidal Anti-Inflammatory Drugs. Clin Ophthalmol 14:1459\u20131466. https:\/\/doi.org\/10.2147\/OPTH.S255441 PubMed PMID: 32546954; PubMed Central PMCID: PMC7266408","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"7375_CR8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/BF02877774","volume":"24","author":"DS Durrie","year":"2007","unstructured":"Durrie DS, Kennard MG, Boghossian AJ (2007) Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). Adv Therapy 24(6):1278\u20131285. https:\/\/doi.org\/10.1007\/BF02877774","journal-title":"Adv Therapy"},{"issue":"9","key":"7375_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jcrs.2007.05.015","volume":"33","author":"T Walters","year":"2007","unstructured":"Walters T, Raizman M, Ernest P, Gayton J, Lehmann R (2007) In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 33(9):1539\u20131545. https:\/\/doi.org\/10.1016\/j.jcrs.2007.05.015. PubMed PMID: 17720067","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"7375_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/OPTH.S1067","volume":"2","author":"BI Gaynes","year":"2008","unstructured":"Gaynes BI, Onyekwuluje A (2008) Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension. Clin Ophthalmol 2(2):355\u2013368. https:\/\/doi.org\/10.2147\/opth.s1067. PubMed PMID: 19668727; PubMed Central PMCID: PMC2693998","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"7375_CR11","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s40123-024-01040-8","volume":"13","author":"N Gomel","year":"2024","unstructured":"Gomel N, Shemesh N, Sorkin N, Levinger N, Levinger S, Hirsch A et al (2024) Postoperative Pain Comparison Between Alcohol-Assisted and Transepithelial Photorefractive Keratectomy Using Nepafenac Treatment: A Novel Study. Ophthalmol Ther 13(12):3049\u20133057. https:\/\/doi.org\/10.1007\/s40123-024-01040-8 PubMed PMID: 39363130; PubMed Central PMCID: PMC11564457","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"7375_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3928\/1081597X","volume":"28","author":"A Meduri","year":"2012","unstructured":"Meduri A, Aragona P, Grenga PL, Roszkowska AM (2012) Effect of basic fibroblast growth factor on corneal epithelial healing after photorefractive keratectomy. J Refract Surg 28(3):220\u2013223. https:\/\/doi.org\/10.3928\/1081597X-20120103-02 PubMed PMID: 22230058","journal-title":"J Refract Surg"},{"issue":"4","key":"7375_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4103\/0301-4738.119420","volume":"62","author":"A Meduri","year":"2014","unstructured":"Meduri A, Scorolli L, Scalinci SZ, Grenga PL, Lupo S, Rechichi M et al (2014) Effect of the combination of basic fibroblast growth factor and cysteine on corneal epithelial healing after photorefractive keratectomy in patients affected by myopia. Indian J Ophthalmol 62(4):424\u2013428. https:\/\/doi.org\/10.4103\/0301-4738.119420 PubMed PMID: 24145571; PubMed Central PMCID: PMC4064216","journal-title":"Indian J Ophthalmol"},{"key":"7375_CR14","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/OPTH.S86812","volume":"9","author":"EM Sobas","year":"2015","unstructured":"Sobas EM, Videla S, Maldonado MJ, Pastor JC (2015) Ocular pain and discomfort after advanced surface ablation: an ignored complaint. Clin Ophthalmol 9:1625\u20131632. https:\/\/doi.org\/10.2147\/OPTH.S86812. PubMed PMID: 26379419; PubMed Central PMCID: PMC4567230","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"7375_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3928\/1081597X-20090201-07","volume":"25","author":"NA Sher","year":"2009","unstructured":"Sher NA, Golben MP, Bond W, Trattler WB, Tauber S, Voirin TG (2009) Topical Bromfenac 0.09% vs Ketorolac 0.4% for the Control of Pain, Photophobia, and Discomfort Following PRK. J Refract Surg 25(2):214\u2013220. https:\/\/doi.org\/10.3928\/1081597X-20090201-07","journal-title":"J Refract Surg"},{"issue":"4","key":"7375_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1155\/2015\/850245","volume":"20","author":"Y Zeng","year":"2015","unstructured":"Zeng Y, Li Y, Gao JH (2015) Application of cold patch in relieving pain after transepithelial photorefractive keratectomy. Pain Res Manag 20(4):195\u2013198 doi:10.1155\/2015\/850245 PubMed PMID: 25992866; PubMed Central PMCID: PMC4532205","journal-title":"Pain Res Manag"},{"issue":"4","key":"7375_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/BF02849978","volume":"24","author":"ED Donnenfeld","year":"2007","unstructured":"Donnenfeld ED, Holland EJ, Durrie DS, Raizman MB (2007) Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. Adv Ther 24(4):852\u2013862 doi:10.1007\/BF02849978 PubMed PMID: 17901034","journal-title":"Adv Ther"},{"issue":"4","key":"7375_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1023\/a:1007049015148","volume":"24","author":"DA Gamache","year":"2000","unstructured":"Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM (2000) Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 24(4):357\u2013370. https:\/\/doi.org\/10.1023\/a:1007049015148 PubMed PMID: 10850857","journal-title":"Inflammation"},{"issue":"3","key":"7375_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3928\/1081597X-20180123-03","volume":"34","author":"GA Kontadakis","year":"2018","unstructured":"Kontadakis GA, Chronopoulou KG, Tsopouridou R, Tabibian D, Kymionis GD (2018) Nepafenac Ophthalmic Suspension 0.3% for the Management of Ocular Pain After Photorefractive Keratectomy. J Refract Surg 34(3):171\u2013176. https:\/\/doi.org\/10.3928\/1081597X-20180123-03. PubMed PMID: 29522226","journal-title":"J Refract Surg"},{"key":"7375_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2147\/PPA.S46667","volume":"8","author":"RK Rajpal","year":"2014","unstructured":"Rajpal RK, Ross B, Rajpal SD, Hoang K (2014) Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence. Patient Prefer Adherence 8:925\u2013931. https:\/\/doi.org\/10.2147\/PPA.S46667. PubMed PMID: 25028541; PubMed Central PMCID: PMC4077855","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"7375_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5935\/0004-2749.20210008","volume":"84","author":"VBP Pereira","year":"2021","unstructured":"Pereira VBP, Torriceli AAM, Garcia R, Bechara SJ, Alves MR (2021) Codeine plus acetaminophen improve sleep quality, daily activity level, and food intake in the early postoperative period after photorefractive keratectomy: a secondary analysis. Arq Bras Oftalmol 84(1):45\u201350. https:\/\/doi.org\/10.5935\/0004-2749.20210008 PubMed PMID: 33470341; PubMed Central PMCID: PMC12289146","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"7375_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40123-019-00215-y","volume":"8","author":"SM Silverstein","year":"2019","unstructured":"Silverstein SM (2019) Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical Pulse Dose. Ophthalmol Ther 8(4):577\u2013587. https:\/\/doi.org\/10.1007\/s40123-019-00215-y","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"7375_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.ophtha.2006.12.029","volume":"114","author":"ED Donnenfeld","year":"2007","unstructured":"Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR (2007) Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 114(9):1653\u20131662 12.029 PubMed PMID: 17445902","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07375-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:08:25Z","timestamp":1784088505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07375-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":23,"alternative-id":["7375"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07375-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a retrospective study conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board at Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (0689-17-TLV).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived by the institutional review board given the retrospective nature of the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}